´ç´¢º´ Ä¡·á ±â±â ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Diabetes Care Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1801908
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 132 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,826,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,515,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,752,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ´ç´¢º´ Ä¡·á ±â±â ½ÃÀåÀº 2024³â¿¡´Â 629¾ï ´Þ·¯¿¡ ´ÞÇß°í, CAGR 12%·Î ¼ºÀåÇÏ¿© 2034³â¿¡´Â 1,930¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ÀÌ ¼ºÀåÀº ¼¼°è ´ç´¢º´ ºÎ´ã Áõ°¡, Áö¼ÓÀûÀÎ ±â¼úÀû µ¹ÆÄ±¸, °ø°ø ¹× ¹Î°£ ºÎ¹®ÀÇ ÀÚ±Ý Á¶´Þ Áõ°¡¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ´ç´¢º´ Ä¡·á ±â±â´Â È¿°úÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ°ú Àν¶¸° Åõ¿©¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ´ç´¢º´ °ü¸®¸¦ Áö¿øÇÏ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ´ç´¢º´ ȯÀÚ ¼ö°¡ ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥, ½Å·Ú¼ºÀÌ ³ô°í, »ç¿ëÇÏ±â Æí¸®ÇÑ ÄÉ¾î ±â±â¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

´ç´¢º´ Ä¡·á ±â±â Market-IMG1

ÀÌ·¯ÇÑ Àåºñ¸¦ º¸´Ù ħ½ÀÀûÀÌÁö ¾Ê°í º¸´Ù Á¤È®ÇÏ°í ºñ¿ë È¿À²ÀûÀÎ °ÍÀ¸·Î ¸¸µå´Â µ¥ ÁßÁ¡À» µÐ ±â¼ú Çõ½ÅÀÌ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇÏ°í º¸´Ù ÄèÀûÇϰí Áúº´°ü¸®¸¦ È®½ÇÈ÷ Çϴ ÷´Ü±â±â¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¶ÇÇÑ ¼ÒºñÀÚÀÇ ±â´ë¿¡ ºÎÀÀÇϱâ À§ÇØ ¿øÈ°ÇÑ Æ÷µµ´ç ÃßÀû°ú Àν¶¸° Àü´ÞÀ» Á¦°øÇÏ´Â º¸´Ù ½º¸¶Æ®ÇÑ ÅëÇÕ ¼Ö·ç¼ÇÀ¸·ÎÀÇ ÀüȯÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 629¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 1,930¾ï ´Þ·¯
CAGR 12%

2024³â Ç÷´ç ¸ð´ÏÅ͸µ Àåºñ ºÎ¹®Àº 422¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2034³â¿¡´Â 1,374¾ï ´Þ·¯¿¡ À̸£°í, CAGR 12.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿ø, Áø´Ü ½ÇÇè½Ç ¹× ÀçÅà °ü¸® ¼³Á¤¿¡¼­ ±¤¹üÀ§ÇÑ »ç¿ëÀÌ ÀÌ·¯ÇÑ ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù. CGM ¹× ÀÚ±â ÃøÁ¤ ¹ÌÅÍ¿Í °°Àº ÀåÄ¡´Â Áö¼ÓÀûÀÎ ¾÷µ¥ÀÌÆ®¸¦ Á¦°øÇÏ¸ç »ç¿ëÀÚ°¡ ½Ç½Ã°£ Æ÷µµ´ç µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ¶óÀÌÇÁ ½ºÅ¸ÀÏ, ½Ä»ç ¼·Ãë·®, Àν¶¸° ÀÏÁ¤À» Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ½É°¢ÇÑ °Ç°­ ¹®Á¦·Î À̾îÁú ¼ö ÀÖ´Â Æ÷µµ´ç ¼öÄ¡ÀÇ ±Þ»ó½Â°ú ±Þ°­Çϸ¦ ÇÇÇϱâ À§Çؼ­´Â Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ µµ±¸´Â 24½Ã°£ ½Ã½ºÅÛ¿¡¼­ Çǵå¹éÀ» Á¦°øÇϹǷΠ»ç¿ëÀÚ´Â ´ç´¢º´ °ü¸®¸¦ Àû±ØÀûÀ¸·Î ¼öÇàÇϰí Àå±âÀûÀÎ ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ȨÄÉ¾î ºÐ¾ß´Â 2024³â 43.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ´ç´¢º´À» Áý¿¡¼­ °ü¸®ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀº ¸¹Àº »ç¶÷µé¿¡°Ô ¸Å¿ì Áß¿äÇÑ ÆíÀǰ¡ µÇ¾ú°í, ÀÚÁÖ ÀÓ»ó ¹æ¹®ÇÒ Çʿ䰡 ¾ø¾îÁ³½À´Ï´Ù. °¡Á¤¿ëÀ¸·Î ¼³°èµÈ Àåºñ´Â ÇöÀç Àü¹®ÀûÀΠȯ°æ¿¡¼­ »ç¿ëµÇ´Â °Í°ú À¯»çÇÑ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ½Ç½Ã°£ Æ÷µµ´ç Ãß¼¼ ºÐ¼®, ¾Ë¶÷, µ¥ÀÌÅÍ ÃßÀû°ú °°Àº °í±Þ ±â´ÉÀº ȯÀÚ°¡ ½Ä´Ü ¼·Ãë·®, Àν¶¸° ¿ë·®, ÀÏ»ó »ýȰ¿¡ ´ëÇÑ ºü¸£°í ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î °áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀçÅà ´ç´¢º´ °ü¸®ÀÇ ÀÌ·¯ÇÑ Áõ°¡ Ãß¼¼´Â ÀÚ¸³°ú »îÀÇ Áú Çâ»óÀ» Ãß±¸ÇÏ´Â »ç¶÷µéÀ» ¸Å·áÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ ´ç´¢º´ Ä¡·á ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 228¾ï ´Þ·¯°¡ µÇ¾ú°í, ÀÌ È£Á¶´Â ´ç´¢º´ Àα¸ Áõ°¡¿Í Çõ½ÅÀûÀÎ ´ç´¢º´ ±â¼úÀÇ ±Þ¼ÓÇÑ Ã¤ÅÃÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¸¸¼º Áúȯ¿¡ °É¸®±â ½¬¿î ³ëÈ­·Î ÀÎÇØ È¿À²ÀûÀÎ ´ç´¢º´ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ±â¼¼´Â ÇÏÀÌ¿£µå °Ç°­ °ü¸® ÀÎÇÁ¶ó Á¢±Ù, À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À, ¿¹¹æ ÀÇ·á ¹× Á¶±â Áø´Ü¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀǽĿ¡ ÀÇÇØ Áö¿øµË´Ï´Ù.

¼¼°è ´ç´¢º´ Ä¡·á ±â±â ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ±â¾÷Àº Tandem Diabetes Care, Becton, Dickinson and Company, Ypsomed Holding, Insulet, Sanofi, Dr. Reddy's Laboratories, Medtronic, Dexcom, Ascensia Diabetes Care, Sinocare, Platinum Equi Laboratories, ARKRAY, DarioHealth, Eli Lilly and Company, Pendiq, Novo Nordisk, F. Hoffmann-La Roche, Bionime, Nova Biomedical µîÀÌ ÀÖ½À´Ï´Ù. ´ç´¢º´ Ä¡·á ±â±â ½ÃÀåÀÇ ¼±µÎ ±â¾÷Àº »ç¿ëÀÚÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¿¡ ´ëÀÀÇϱâ À§ÇØ Á¦Ç° Çõ½ÅÀÇ °­È­¿Í Æ÷Æ®Æú¸®¿ÀÀÇ ´Ù¾çÈ­¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â Æ÷µµ´ç ÃßÀûÀ» °³¼±Çϱâ À§ÇØ ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼® ¹× ºí·çÅõ½º ¿¬°áÀ» °®Ãá ½º¸¶Æ® ¿þ¾î·¯ºí ÀåÄ¡¸¦ µµÀÔÇß½À´Ï´Ù. µðÁöÅÐ °Ç°­ Ç÷§Æû°úÀÇ Àü·«Àû Á¦ÈÞ´Â µ¥ÀÌÅ͸¦ º¸´Ù ±¤¹üÀ§ÇÑ °Ç°­ »ýŰ迡 ÅëÇÕÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. M&Aµµ Áö¸®Àû Á¸Àç È®´ë ¹× »õ·Î¿î °í°´ ±â¹Ý¿¡ ´ëÇÑ ¾×¼¼½º¿¡ Ȱ¿ëµË´Ï´Ù. R&D¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ·Î Àåºñ´Â ħ½ÀÀÌ Àû°í Á¤È®ÇÏ°í »ç¿ëÇϱ⠽±½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Á¦Ç°º°, 2021³â-2034³â

Á¦6Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021³â-2034³â

Á¦7Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ±¹°¡º°, 2021³â-2034³â

Á¦8Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Diabetes Care Devices Market was valued at USD 62.9 billion in 2024 and is estimated to grow at a CAGR of 12% to reach USD 193 billion by 2034. This growth is driven by the rising global diabetes burden, continuous technological breakthroughs, and increased funding from both public and private sectors. Diabetes care devices are essential medical tools that support individuals in managing diabetes by enabling effective blood glucose monitoring and insulin administration. As the number of individuals living with diabetes continues to rise worldwide, the demand for reliable and user-friendly care devices continues to grow.

Diabetes Care Devices Market - IMG1

Innovations focused on making these tools less invasive, more accurate, and cost-effective are propelling demand. Companies are investing heavily in R&D to bring forward advanced devices that ensure better comfort and disease management. The market is also experiencing a shift toward smarter, integrated solutions that provide seamless glucose tracking and insulin delivery to meet growing consumer expectations.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$62.9 Billion
Forecast Value$193 Billion
CAGR12%

In 2024, the blood glucose monitoring devices segment generated USD 42.2 billion and projected to hit USD 137.4 billion by 2034, growing at a CAGR of 12.7%. Their extensive use in hospitals, diagnostic labs, and homecare setups underpins this growth. Devices like CGMs and self-monitoring meters offer continuous updates, helping users regulate their lifestyle, food intake, and insulin schedules based on real-time glucose data. Regular monitoring is vital to avoid spikes or drops in glucose levels, which can lead to serious health issues. These tools provide round-the-clock feedback, ensuring users remain proactive in their diabetes management and minimizing long-term complications.

The home care segment held 43.8% share in 2024. The ability to manage diabetes at home has become a crucial convenience for many, eliminating the need for frequent clinical visits. Devices designed for home use now offer similar capabilities as those used in professional settings. Advanced features like real-time glucose trend analysis, alarms, and data tracking help patients make quick and informed decisions about food intake, insulin doses, and daily routines. This growing trend of home-based diabetes management continues to attract individuals looking for independence and improved quality of life.

United States Diabetes Care Devices Market generated USD 22.8 billion in 2024. This strong performance is due to the growing diabetic population and the rapid adoption of innovative diabetes technologies. An aging population more prone to chronic conditions further intensifies demand for efficient diabetes management solutions. The market's momentum in the region is supported by access to high-end healthcare infrastructure, favorable reimbursement scenarios, and consumer awareness around preventative care and early diagnosis.

Key companies influencing the Global Diabetes Care Devices Market include Tandem Diabetes Care, Becton, Dickinson and Company, Ypsomed Holding, Insulet, Sanofi, Dr. Reddy's Laboratories, Medtronic, Dexcom, Ascensia Diabetes Care, Sinocare, Platinum Equity Advisors, Abbott Laboratories, ARKRAY, DarioHealth, Eli Lilly and Company, Pendiq, Novo Nordisk, F. Hoffmann-La Roche, Bionime, and Nova Biomedical. Leading players in the diabetes care devices market are focusing on enhancing product innovation and portfolio diversification to meet the evolving needs of users. Companies are introducing smart, wearable devices with real-time data analytics and Bluetooth connectivity to improve glucose tracking. Strategic collaborations with digital health platforms help integrate data into broader health ecosystems. Mergers and acquisitions are also being used to expand geographic presence and access new customer bases. Continuous investments in R&D ensure devices become less invasive, more accurate, and easier to use.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)

Chapter 8 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â